26rhk188 10.3205/26rhk188 urn:nbn:de:0183-26rhk1881 Meeting Abstract Patschan Patschan Susann S

Medizinische Hochschule Brandenburg, Brandenburg, Deutschland

author Fuhrmann Fuhrmann Max M

Medizinische Hochschule Brandenburg, Brandenburg, Deutschland

author Claus Claus Inga I

Medizinische Hochschule Brandenburg, Brandenburg, Deutschland

author Patschan Patschan Daniel D

Medizinische Hochschule Brandenburg, Brandenburg, Deutschland

author German Medical Science GMS Publishing House

Düsseldorf

610 20260909 engl This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). M0656 188 Deutsche Gesellschaft für Rheumatologie Deutsche Gesellschaft für Orthopädische Rheumatologie Gesellschaft für Kinder- und Jugendrheumatologie 54. Kongress der Deutschen Gesellschaft für Rheumatologie und Klinische Immunologie (DGRh), 36. Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR), 40. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh) Deutscher Rheumatologiekongress 2026 Rheumatoide Arthritis Leipzig 20260909 20260912 RA.02 TextIntroduction: Rheumatoid arthritis (RA) and chronic kidney disease (CKD) are common chronic conditions associated with substantial morbidity and increased cardiovascular risk. The coexistence of CKD in RA patients has important therapeutic implications, particularly regarding the safe use and dosing of disease-modifying antirheumatic drugs (DMARDs). While CKD prevalence in the general population range between 10% and 15%, data on CKD and the use of DMARDs in hospitalized RA patients remain limited. Lately, we identified a CKD prevalence of nearly 20% in outpatient RA individuals („historic“ cohort).Methods: This retrospective observational cohort study analyzed hospitalized patients with RA treated at Brandenburg University Hospital between 2023 and 2024. Demographic characteristics, RA-related parameters, kidney function, comorbidities, and medication data were extracted from the hospital database. CKD was defined according to KDIGO 2024 criteria. DMARD dosing was assessed for appropriateness based on kidney excretory function according to the eGFR (CKD-EPI). Key findings were compared with data from a previously analyzed outpatient RA (historic) cohort.Results: A total of 310 RA patients were included (63.9% female, mean age 73.5 ± 11.1 years). CKD was present in 35.16% of patients. Individuals with CKD were significantly older (79.17 ± 9.16 vs. 70.42 ± 10.79 years, p < 0.001) and had higher CRP levels (24.08 ± 30.52 vs. 15.18 ± 22.33 mg/L, p = 0.01). DMARD therapy was used in 43.12% of CKD patients, with appropriate dose adjustment in 89.8% of cases. Compared with a (historic) outpatient RA cohort (n = 466), CKD prevalence was significantly higher among hospitalized patients (35.16% vs. 19.74%, p < 0.001), while DMARD use was less frequent (43.12% vs. 80.43%, p < 0.001). The rate of correct renal dose adjustment was comparable between cohorts.Conclusion: Chronic kidney disease (CKD) is highly prevalent among hospitalized patients with rheumatoid arthritis (RA) and is more common than in outpatient populations. Although hospitalized patients receive fewer disease-modifying antirheumatic drugs (DMARDs), dose adjustments for renal function are generally appropriate. These findings underscore the need for routine assessment of kidney function in RA patients to optimize treatment strategies and minimize therapy-related risks. 0 0 0 0